- |||||||||| letrozole / Generic mfg.
Trial completion date, Trial primary completion date: Evaluation of IM Letrozole ISM (clinicaltrials.gov) - Oct 28, 2022 P1, N=120, Active, not recruiting, The gene expression analysis using chimeric mice with humanized liver revealed that the mechanisms are letrozole specific and, therefore, may be repurposed for the treatment of liver fibrosis. Trial completion date: Jul 2022 --> Mar 2023 | Trial primary completion date: Jul 2022 --> Mar 2023
- |||||||||| Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date, Tumor mutational burden, Metastases: BioItaLEE: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant (clinicaltrials.gov) - Oct 24, 2022 P3, N=287, Active, not recruiting, Trial completion date: Aug 2022 --> Dec 2022 Trial completion date: Dec 2022 --> Jul 2024 | Trial primary completion date: Jul 2022 --> Jun 2024
- |||||||||| letrozole / Generic mfg.
Laparoscopic oocyte retrieval for fertility preservation in a patient with squamous cell carcinoma of the vagina () - Oct 23, 2022 - Abstract #ESGE2022ESGE_788; In order to limit high estrogens levels, letrozole has been used during the controlled ovarian stimulation (COS)...Laparoscopy oocyte retrieval, performed under regional anaesthesia, can be performed in ambulatory setting and could be considered an effective strategy to preserve fertility in patients and to prevent the risk of tumour spillage. https://player.vimeo.com/video/708292542?autoplay=1
- |||||||||| Ibrance (palbociclib) / Pfizer
A CASE OF PSEUDOCIRRHOSIS IN METASTATIC BREAST CANCER AFTER TREATMENT WITH PALBOCICLIB () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2198; This case of pseudocirrhosis, with advanced GI and peritoneal metastases but no overt liver lesions, supports previous literature. The primary site of toxic injury is suspected to be sinusoidal endothelial cells with resultant circulatory compromise of centrilobular hepatocytes, fibrosis, and obstruction of liver blood flow.
- |||||||||| letrozole / Generic mfg.
Sex hormones impact the response to immunotherapy in obese male mice. (Foyer mezzanine) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_361; Obese males were treated with the aromatase inhibitor letrozole in order to decrease the estrogen/androgen ratio...Conclusions These results demonstrate that the estrogen/androgen ratio can determine the response to ICI in obese mice and support the hypothesis that sex hormones may contribute to ICI sensitivity in obese male patients with melanoma. This concept opens the path to investigate whether serum sex hormones levels could be used as biomarkers for response to ICI and whether targeting the hormonal balance may be a relevant therapeutic strategy to improve the response to ICI.
- |||||||||| letrozole / Generic mfg.
Journal: Considerations when treating male pubertal delay pharmacologically. (Pubmed Central) - Oct 21, 2022 Aromatase inhibitors have arisen as an interesting alternative for boy with CDGP and short stature. Gonadotrophin therapy seems more physiological in patients with central hypogonadism, but its relative efficacy and most adequate timing still need to be established.
- |||||||||| Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy: Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer (clinicaltrials.gov) - Oct 21, 2022 P2, N=75, Completed, Gonadotrophin therapy seems more physiological in patients with central hypogonadism, but its relative efficacy and most adequate timing still need to be established. Trial completion date: Nov 2020 --> Mar 2022 | Trial primary completion date: Nov 2020 --> Mar 2022
- |||||||||| letrozole / Generic mfg.
Journal: Facebook as a source of access to medicines. (Pubmed Central) - Oct 20, 2022 These were opioids (n = 7; 1.71%), benzodiazepines (n = 2; 0.48%), clomifene (n = 1; 0.24%), and letrozole (n = 1; 0.24%)...Medicines offered on Facebook were mainly accessible for free. The scope and the number of medications offered on Facebook should make this issue a hazardous phenomenon.
- |||||||||| letrozole / Generic mfg., tamoxifen / Generic mfg., capecitabine / Generic mfg.
PREVALENCE OF DRUG INTERACTIONS AND POTENTIALLY INAPPROPRIATE MEDICATIONS IN CANCER PATIENTS () - Oct 19, 2022 - Abstract #AIOM2022AIOM_101; Preliminary data from this study demon- strate the necessity of careful treatment evaluation to pre- vent poor clinical outcomes due to drug interactions and to avoid the prescription of potentially inappropriate drugs in elderly cancer patients, suffering from concomitant dis- eases. A drug interaction checker tool could improve clini- cal decision-making and patient safety.
- |||||||||| letrozole / Generic mfg.
Preclinical, Journal: In vitro cytotoxicity and anti-cancer drug release behavior of methionine-coated magnetite nanoparticles as carriers. (Pubmed Central) - Oct 14, 2022 The appearance of a new peak for C≡N confirms the formation of Letrozole-loaded carrier in the FTIR...Also, the preparation had been evaluated for determining its cytotoxicity using MCF-7, MDA-MB-231, and MCF10A cells as an in vitro model, and the result vitro experiments showed that CoFeO@Methionine could significantly reduce cancer in cells model. These results demonstrate that core-shell nanoparticle was prepared is biocompatible and have potential use as drug delivery.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: LaPemERLA: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole (clinicaltrials.gov) - Oct 14, 2022 P2, N=40, Not yet recruiting, These results demonstrate that core-shell nanoparticle was prepared is biocompatible and have potential use as drug delivery. Trial completion date: Mar 2026 --> Dec 2026 | Initiation date: Apr 2022 --> Jan 2023 | Trial primary completion date: Dec 2024 --> Dec 2025
- |||||||||| Ibrance (palbociclib) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date: ASPIRE: Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (clinicaltrials.gov) - Oct 14, 2022 P2, N=38, Active, not recruiting, Trial completion date: Mar 2026 --> Dec 2026 | Initiation date: Apr 2022 --> Jan 2023 | Trial primary completion date: Dec 2024 --> Dec 2025 Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
- |||||||||| letrozole / Generic mfg.
Preclinical, Journal: Delayed Implantation Induced by Letrozole in Mice. (Pubmed Central) - Oct 12, 2022 Progesterone supplementation could rescue decidualization failure in the mice. Collectively, we established a new model of delayed implantation by letrozole, which can be easily applied to study the effect and mechanisms of delay of embryo implantation on the progression of late pregnancy events.
- |||||||||| PF-07248144 / Pfizer
Trial completion date, Trial primary completion date, Metastases: C4551001: Study of PF-07248144 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 12, 2022 P1, N=108, Recruiting, Letrozole depriving the placenta of estrogen that had vascular supporting signals resulted in destroying the vascular network with marked apoptosis. Trial completion date: Apr 2025 --> Oct 2025 | Trial primary completion date: Nov 2023 --> May 2024
- |||||||||| Ibrance (palbociclib) / Pfizer
Trial completion, Trial completion date, Trial primary completion date: Palbociclib and FES PET (clinicaltrials.gov) - Oct 12, 2022 P2, N=30, Completed, Trial completion date: Apr 2025 --> Oct 2025 | Trial primary completion date: Nov 2023 --> May 2024 Active, not recruiting --> Completed | Trial completion date: May 2022 --> Sep 2022 | Trial primary completion date: May 2022 --> Sep 2022
- |||||||||| chlorogenic acid / Jiuzhang Biotech
Preclinical, Journal: Therapeutic Investigation of Standardized Aqueous Methanolic Extract of Bitter Melon (Momordica charantia L.) for Its Potential against Polycystic Ovarian Syndrome in Experimental Animals' Model: In Vitro and In Vivo Studies. (Pubmed Central) - Oct 11, 2022 HPLC analysis of standardized aqueous methanolic extract of bitter melon revealed the presence of various phytochemicals such as quercetin, gallic acid, benzoic acid, chlorogenic acid, syringic acid, p-coumaric acid, ferulic acid, and cinnamic acid...Letrozole (1 mg/kg p.o.) was used for four weeks to induce PCOS in twenty rats...Animals were further divided into four groups, with one group as PCOS group, and the remaining three are treated with standardized extract of bitter melon (500 mg/kg p.o.), bitter melon plus metformin (500 mg/kg p.o.), and metformin alone for the period of next four weeks...Lipid profile and antioxidant enzymes status were also significantly (p < 0.001) improved. In conclusion, the study validates the bitter melon potential as an insulin sensitizer and ovulation enhancer and authenticates its potential in PCOS management.
|